Investment
Features
FeesSafety
Academy
More
Pluang+

Compare HubSpot Inc (HUBS) vs Smith & Nephew plc (SNN) Price & Performance

HubSpot IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

HubSpot Inc vs Smith & Nephew plc — how do they compare? HubSpot Inc trades at $229.3 (market cap $11.56B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: HubSpot Inc and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays a 2.95% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Smith & Nephew plc for 121 Days on average.

HUBSSNN
Market Cap
$11.56B$11.10B
Volume
1,891,2871,051,703
Sector
TechnologyHealth
52-Week High
$494.58$37.17
52-Week Low
$170.39$26.42
Typical Hold Time
78 Days121 Days
Enterprise Value
$10.46B$14.13B
Dividend Yield
—2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

HubSpot Inc

HubSpot (HUBS) trades at $228.96, up 3.93% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth, reaching $3.13B in 2025 with net income turning positive at $45.91M. Recent analyst day highlighted AI strategy enhancements and margin expansion targets, while institutional buying and positive earnings beats support investor confidence. Technical indicators show the stock trading near pivot point resistance at $228 with RSI suggesting potential overbought conditions.

Outlook remains positive with 57% analyst buy ratings and $243.65 consensus target, though high P/E of 82.5x demands sustained growth execution. Key risks include AI competition pressure and valuation sensitivity to earnings momentum. The transition to profitability and strong cash flow generation provide fundamental support for continued upside potential.

Smith & Nephew plc

SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.

The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HUBS
1% Buy99% Sell
Avg holding period · 78 Days
SNN

No sentiment data available yet.

Top news

Latest headlines on both assets

About HubSpot Inc

HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.

Read more on HUBS →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →